Endophthalmitis News and Research

RSS
New ocular inserts allow patient's cornea to absorb more antibiotics

New ocular inserts allow patient's cornea to absorb more antibiotics

Researchers working towards developing novel stem cell approaches for glaucoma

Researchers working towards developing novel stem cell approaches for glaucoma

Risk for endophthalmitis no higher with Avastin, finds study

Risk for endophthalmitis no higher with Avastin, finds study

hESC-derived cells offer source of macular tissue repair and replacement

hESC-derived cells offer source of macular tissue repair and replacement

Trained nurses administer AMD treatments as safely and effectively as doctors

Trained nurses administer AMD treatments as safely and effectively as doctors

Success for nurse practitioner-delivered intravitreal injection service for wAMD

Success for nurse practitioner-delivered intravitreal injection service for wAMD

Study identifies best course of treatment for endophthalmitis

Study identifies best course of treatment for endophthalmitis

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Antibiotic prophylaxis after IVT may be harmful

Antibiotic prophylaxis after IVT may be harmful

Intravitreal ranibizumab shows little benefit after hemorrhage

Intravitreal ranibizumab shows little benefit after hemorrhage

Bayer submits MAA in Europe for EYLEA to treat macular edema after CRVO

Bayer submits MAA in Europe for EYLEA to treat macular edema after CRVO

EC approves Regeneron’s EYLEA for treatment of wet AMD

EC approves Regeneron’s EYLEA for treatment of wet AMD